Exploring Pyroptosis-related Signature Genes and Potential Drugs in Ulcerative Colitis by Transcriptome Data and Animal Experimental Validation
- PMID: 38656456
- DOI: 10.1007/s10753-024-02025-2
Exploring Pyroptosis-related Signature Genes and Potential Drugs in Ulcerative Colitis by Transcriptome Data and Animal Experimental Validation
Abstract
Ulcerative colitis (UC) is an idiopathic, relapsing inflammatory disorder of the colonic mucosa. Pyroptosis contributes significantly to UC. However, the molecular mechanisms of UC remain unexplained. Herein, using transcriptome data and animal experimental validation, we sought to explore pyroptosis-related molecular mechanisms, signature genes, and potential drugs in UC. Gene profiles (GSE48959, GSE59071, GSE53306, and GSE94648) were selected from the Gene Expression Omnibus (GEO) database, which contained samples derived from patients with active and inactive UC, as well as health controls. Gene Set Enrichment Analysis (GSEA), Weighted Gene Co-expression Network Analysis (WGCNA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed on microarrays to unravel the association between UC and pyroptosis. Then, differential expressed genes (DEGs) and pyroptosis-related DEGs were obtained by differential expression analyses and the public database. Subsequently, pyroptosis-related DEGs and their association with the immune infiltration landscape were analyzed using the CIBERSORT method. Besides, potential signature genes were selected by machine learning (ML) algorithms, and then validated by testing datasets which included samples of colonic mucosal tissue and peripheral blood. More importantly, the potential drug was screened based on this. And these signature genes and the drug effect were finally observed in the animal experiment. GSEA and KEGG enrichment analyses on key module genes derived from WGCNA revealed a close association between UC and pyroptosis. Then, a total of 20 pyroptosis-related DEGs of UC and 27 pyroptosis-related DEGs of active UC were screened. Next, 6 candidate genes (ZBP1, AIM2, IL1β, CASP1, TLR4, CASP11) in UC and 2 candidate genes (TLR4, CASP11) in active UC were respectively identified using the binary logistic regression (BLR), least absolute shrinkage and selection operator (LASSO), random forest (RF) analysis and artificial neural network (ANN), and these genes also showed high diagnostic specificity for UC in testing sets. Specially, TLR4 was elevated in UC and further elevated in active UC. The results of the drug screen revealed that six compounds (quercetin, cyclosporine, resveratrol, cisplatin, paclitaxel, rosiglitazone) could target TLR4, among which the effect of quercetin on intestinal pathology, pyroptosis and the expression of TLR4 in UC and active UC was further determined by the murine model. These findings demonstrated that pyroptosis may promote UC, and especially contributes to the activation of UC. Pyroptosis-related DEGs offer new ideas for the diagnosis of UC. Besides, quercetin was verified as an effective treatment for pyroptosis and intestinal inflammation. This study might enhance our comprehension on the pathogenic mechanism and diagnosis of UC and offer a treatment option for UC.
Keywords: active ulcerative colitis; bioinformatics analysis; inactive ulcerative colitis; machine learning; pyroptosis; signature genes; ulcerative colitis.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing Interests: The authors declare no competing interests.
Similar articles
-
Constructing a screening model to obtain the functional herbs for the treatment of active ulcerative colitis based on herb-compound-target network and immuno-infiltration analysis.Naunyn Schmiedebergs Arch Pharmacol. 2024 Jul;397(7):4693-4711. doi: 10.1007/s00210-023-02900-z. Epub 2023 Dec 20. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38117365 Free PMC article.
-
Identification of a Novel Activated NK-Associated Gene Score Associated with Diagnosis and Biological Therapy Response in Ulcerative Colitis.Digestion. 2025;106(1):1-22. doi: 10.1159/000540939. Epub 2024 Aug 23. Digestion. 2025. PMID: 39182484 Free PMC article.
-
Exploring Immune Cell Infiltration and Small Molecule Compounds for Ulcerative Colitis Treatment.Genes (Basel). 2024 Nov 29;15(12):1548. doi: 10.3390/genes15121548. Genes (Basel). 2024. PMID: 39766817 Free PMC article.
-
Construction of a molecular inflammatory predictive model with histone modification-related genes and identification of CAMK2D as a potential response signature to infliximab in ulcerative colitis.Front Immunol. 2024 Jan 11;14:1282136. doi: 10.3389/fimmu.2023.1282136. eCollection 2023. Front Immunol. 2024. PMID: 38274809 Free PMC article.
-
Unveiling the key genes, environmental toxins, and drug exposures in modulating the severity of ulcerative colitis: a comprehensive analysis.Front Immunol. 2023 Jul 19;14:1162458. doi: 10.3389/fimmu.2023.1162458. eCollection 2023. Front Immunol. 2023. PMID: 37539055 Free PMC article. Review.
Cited by
-
Regulation of pyroptosis by natural products in ulcerative colitis: mechanisms and therapeutic potential.Front Pharmacol. 2025 Apr 9;16:1573684. doi: 10.3389/fphar.2025.1573684. eCollection 2025. Front Pharmacol. 2025. PMID: 40271055 Free PMC article. Review.
-
Mechanism of cell death and its application in the repair of inflammatory bowel disease by mesenchymal stem cells.Front Immunol. 2025 Jun 4;16:1597462. doi: 10.3389/fimmu.2025.1597462. eCollection 2025. Front Immunol. 2025. PMID: 40534879 Free PMC article. Review.
-
Unveiling the Therapeutic Potential of Jiawei Jianpi Huoyu Formula in Ulcerative Colitis: A Multi-Strategies and Experimental Study Integrating Network Pharmacology, Machine Learning, and Mendelian Randomization.J Inflamm Res. 2025 Aug 12;18:10885-10903. doi: 10.2147/JIR.S527482. eCollection 2025. J Inflamm Res. 2025. PMID: 40823360 Free PMC article.
References
-
- Cohen, R.D., et al. 2010. Systematic review: The costs of ulcerative colitis in Western countries. Alimentary Pharmacology & Therapeutics 31 (7): 693–707. - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Medical